Loading...
Please wait, while we are loading the content...
Similar Documents
Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
| Content Provider | Scilit |
|---|---|
| Author | Yang, Jiangping Han, Jiaqi Tian, Maolang Tian, Kun Liao, Wenjun Yan, Xi |
| Copyright Year | 2020 |
| Abstract | Purpose: Ribociclib has provided significant improvements in progression-free survival (PFS) and overall survival (OS) of postmenopausal patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). However, given the high cost of ribociclib, its value must be evaluated based on cost-effectiveness. Thus, we aimed to explore the cost-effectiveness of ribociclib for postmenopausal patients with HR-positive and HER2-negative ABC. Methods: A comprehensive Markov model was developed to estimate the cost-effectiveness of ribociclib plus fulvestrant versus placebo plus fulvestrant as first-line treatment for HR-positive, HER2-negative ABC. Variables were estimated based on data from the randomized Phase III MONALEESA-3 trial. Ten-year values were estimated for quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Direct treatment costs were estimated from the perspective of a United States payer. One-way and probabilistic sensitivity analyses were conducted to confirm the model’s robustness. Results: Ribociclib plus fulvestrant increased the treatment cost by $382,172 and provided 0.47 QALYs, relative to fulvestrant alone, which corresponded to an ICER of $813,132 per QALY. Sensitivity analyses revealed that ribociclib was unlikely to be cost-effective even under the most favorable assumptions. When the cost of ribociclib was <$1,384, there was a > 50% chance of cost-effectiveness at a willingness-to-pay threshold of $150,000/QALY. Subgroup analyses also confirmed that ribociclib was not cost-effective. Conclusion: At current drug prices in the United States, ribociclib is unlikely to be cost-effective for treating postmenopausal patients with HR-positive HER2-negative ABC. Despite the clinical benefits of ribociclib, its cost would need to decrease to provide more favorable economic outcomes. |
| Related Links | https://www.dovepress.com/getfile.php?fileID=64802 |
| Ending Page | 12913 |
| Page Count | 9 |
| Starting Page | 12905 |
| ISSN | 11791322 |
| DOI | 10.2147/cmar.s284556 |
| Journal | Cancer Management and Research |
| Volume Number | 12 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2020-12-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Cancer Management and Research Oncology Breast Cancer Cost-effectiveness Fulvestrant Hormone Receptor Positive Ribociclib |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |
